Research reveals that the APOE2 gene protects brain cells by reducing DNA damage and enhancing recovery from stress, potentially paving the way for Alzheimer's treatments.
New Delhi, India Jul 24, 2026 ALN: Individuals carrying the APOE2 variant of the apolipoprotein E gene are known to enjoy longer lifespans and a reduced risk of developing Alzheimer's disease. While this advantage has been recognized for years, the underlying biological mechanisms remained largely unexplored until now.
A recent study conducted by the Buck Institute for Research on Aging and published in the journal Aging Cell provides new insights into how APOE2 aids neurons in safeguarding their DNA and avoiding senescence—a state of cellular damage and dysfunction that increases with age and contributes to neurodegeneration.
The findings suggest that the role of APOE extends beyond its well-known function in cholesterol transport, indicating that different variants of the gene may influence the ability of brain cells to preserve and repair their genetic material over time.
“For years, we’ve known that APOE2 carriers tend to live longer and have a lower risk of Alzheimer’s, but the protective mechanism has been a black box,” stated Dr. Lisa M. Ellerby, the senior author and a professor at the Buck Institute. “Our research demonstrates that APOE2 neurons are more effective at preventing and repairing DNA damage, and they resist the cellular aging processes that contribute significantly to decline in later life. Our findings open up entirely new therapeutic avenues.”
The APOE gene exists in three primary forms: APOE2, APOE3, and APOE4. These variants differ by just two amino acids, yet they have markedly different impacts on brain aging. APOE4 is recognized as the strongest genetic risk factor for late-onset Alzheimer's disease, typically manifesting after the age of 65. Conversely, APOE2 has consistently been associated with longevity and a decreased risk of dementia in population studies.
To investigate how these APOE variants affect neuronal aging, researchers utilized human induced pluripotent stem cells (iPSCs) that were genetically modified to differ solely at the APOE locus. They differentiated these cells into two types of neurons: inhibitory GABAergic neurons and excitatory glutamatergic neurons, allowing for a comparative analysis of how APOE2, APOE3, and APOE4 influenced each cell type.
The study revealed that neurons expressing APOE2 accumulated significantly less DNA damage compared to those with other gene variants. Through bulk and single-cell RNA sequencing, it was observed that APOE2 GABAergic neurons activated pathways crucial for DNA repair and damage response. In contrast, APOE4 neurons exhibited gene activity patterns linked to Alzheimer's disease.
Direct assessments of DNA strand breaks corroborated these findings, indicating that APOE2 neurons experienced markedly less DNA damage than their counterparts carrying APOE3 or APOE4.
Moreover, APOE2 neurons demonstrated greater resistance to senescence. When subjected to radiation or the chemotherapy drug doxorubicin—both known to inflict DNA damage and stress—APOE2 neurons displayed lower levels of senescence markers, such as p16 and CRYAB, compared to APOE3 and APOE4 neurons. They also maintained smaller nucleoli and a more intact nuclear architecture, suggesting a ier internal cellular structure.
The researchers further explored whether the protective effects of APOE2 could extend to neurons carrying the APOE4 variant. When recombinant APOE2 protein was introduced to APOE4 neurons, a reduction in DNA damage signaling following radiation exposure was observed. This finding hints that some protective benefits of APOE2 may be transferable, rather than exclusive to individuals born with this gene variant.
Similar results were noted in mouse models. Older APOE2 knock-in mice exhibited smaller nucleoli, elevated levels of the nuclear scaffolding protein Lamin A/C, and better-preserved heterochromatin in the hippocampus compared to mice with APOE3 or APOE4. These characteristics are indicative of ier aging in brain cells and provide further validation of the human neuron findings.
DNA damage and cellular senescence are increasingly acknowledged as significant contributors to aging and age-related diseases, including Alzheimer's. Dr. Ellerby remarked, “Until now, the focus within the APOE research community has largely been on lipid metabolism and amyloid-beta biology. By demonstrating that APOE alleles also modulate how neurons protect their genome, this study links a major longevity gene to two of the most actively studied hallmarks of aging.”
The implications of these findings suggest that treatments aimed at enhancing DNA repair or eliminating senescent cells from the brain could potentially replicate some of the natural advantages conferred by APOE2. Such strategies might ultimately benefit individuals carrying the higher-risk APOE4 variant.
“What surprised us was the consistency of the results across two distinct neuron types and between human cells and mouse brain tissue,” commented Dr. Cristian Gerónimo-Olvera, co-first author and postdoctoral fellow at the Buck Institute. “APOE2 neurons are not only less damaged at baseline but also recover more effectively under stress.”
While the precise mechanisms by which APOE2 stabilizes the nuclear envelope and enhances DNA repair remain to be fully elucidated, future research will focus on whether APOE2-mimetic compounds or targeted DNA repair therapies can offer similar protective effects for individuals with the APOE4 variant, who are at the highest genetic risk for Alzheimer's disease.
Other collaborators include: Stephen M. Scheeler, Carlos Galicia Aguirre, Genesis Vega-Hormazabal, Daniela Garcia, Long Wu, Natalia Murad, Kevin Schneider, Kenneth A. Wilson, Nikola T. Markov, Jesse Simons, Akos A. Gerencser, Emily Parlan, Eric Verdin, Judith Campisi, Tara E. Tracy, David Furman, Simon Melov, Buck Institute; Sicheng Song and Sean D. Mooney, Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington.
This work was supported by the National Institute on Aging (R01AG061879, P01AG066591, T32 AG000266), the Paul F. Glenn Center for Biology of Aging, the Hevolution Foundation (HF-PART-23-1422047), and a CatalystX award from Alex and Bob Griswold and the Valley Foundation Fellowship.
To learn more about the latest developments in Diseases & Conditions, stay updated with our exclusive reports and analyses on AiLensNews.
